Reuters
16 Jan 2026, 19:44 UTC · 40w ago
Verdict
Headline takes no side. We score AMRN +0.20 across two claims — slightly bullish.
+0.20slightly bullish
More positive than 53% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
2 claims · scored −1 bearish … +1 bullish
The U.S. Supreme Court will hear a patent dispute regarding Amarin Pharma's cardiovascular drug Vascepa that could broadly impact generic drug makers and their use of 'skinny labels'.
More positive than 99% of claims this week
The legal dispute directly involves Amarin Pharma's cardiovascular drug Vascepa.
Continue reading
5 related stories
More positive than 93% of claims this week
Which stocks this story touches
More positive than 53% of ticker scores this week
The Supreme Court agreeing to hear a patent dispute potentially provides a path to protect its drug from generic competition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
−14.5%
Price is moving against the score
$12.74 vs $14.90 close before publication (Jan 15) · not market-adjusted
AMRN chart →
